☰

cached image

Kayla J. Temple, Ph.D. - Publications

Affiliations: 
2007-2013 Purdue University, West Lafayette, IN, United States 
 2014- Neuroscience Drug Discovery Vanderbilt University, Nashville, TN 
Website:
https://www.linkedin.com/pub/kayla-temple/5a/556/a54
Tree Info Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Long MF, Capstick RA, Spearing PK, Engers JL, Gregro AR, Bollinger SR, Chang S, Luscombe VB, Rodriguez AL, Cho HP, Niswender CM, Bridges TM, Jeffrey Conn P, Lindsley CW, Engers DW, ... Temple KJ, et al. Development of structurally distinct tricyclic M positive allosteric modulator (PAM) chemotypes - Part 2. Bioorganic & Medicinal Chemistry Letters. 128416. PMID 34710625 DOI: 10.1016/j.bmcl.2021.128416  0.43
2019 Temple KJ, Long MF, Engers JL, Watson KJ, Chang S, Luscombe VB, Rodriguez AL, Niswender CM, Bridges TM, Jeffrey Conn P, Engers DW, Lindsley CW. Discovery of structurally distinct tricyclic M positive allosteric modulator (PAM) chemotypes. Bioorganic & Medicinal Chemistry Letters. 126811. PMID 31787491 DOI: 10.1016/J.Bmcl.2019.126811  0.451
2019 Temple KJ, Engers JL, Long MF, Watson KJ, Chang S, Luscombe VB, Jenkins MT, Rodriguez AL, Niswender CM, Bridges TM, Jeffrey Conn P, Engers DW, Lindsley CW. Discovery of a novel 2,3-dimethylimidazo[1,2-a]pyrazine-6-carboxamide M positive allosteric modulator (PAM) chemotype. Bioorganic & Medicinal Chemistry Letters. 126812. PMID 31784320 DOI: 10.1016/J.Bmcl.2019.126812  0.48
2019 Temple KJ, Engers JL, Long MF, Gregro AR, Watson KJ, Chang S, Jenkins MT, Luscombe VB, Rodriguez AL, Niswender CM, Bridges TM, Conn PJ, Engers DW, Lindsley CW. Discovery of a novel 3,4-dimethylcinnoline carboxamide M positive allosteric modulator (PAM) chemotype via scaffold hopping. Bioorganic & Medicinal Chemistry Letters. 126678. PMID 31537424 DOI: 10.1016/j.bmcl.2019.126678  0.407
2019 Maksymetz J, Joffe ME, Moran SP, Stansley BJ, Li B, Temple K, Engers DW, Lawrence JJ, Lindsley CW, Conn PJ. M Muscarinic Receptors Modulate Fear-Related Inputs to the Prefrontal Cortex: Implications for Novel Treatments of Posttraumatic Stress Disorder. Biological Psychiatry. PMID 31003787 DOI: 10.1016/J.Biopsych.2019.02.020  0.378
2018 Rigg RA, Healy LD, Chu TT, Ngo ATP, Mitrugno A, Zilberman-Rudenko J, Aslan JE, Hinds MT, Vecchiarelli LD, Morgan TK, Gruber A, Temple KJ, Lindsley CW, Duvernay MT, Hamm HE, et al. Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions. Platelets. 1-10. PMID 30560697 DOI: 10.1080/09537104.2017.1406076  0.424
2016 Jeffries DE, Witt JO, McCollum AL, Temple KJ, Hurtado MA, Harp JM, Blobaum AL, Lindsley CW, Hopkins CR. Discovery, characterization and biological evaluation of a novel (R)-4,4-difluoropiperidine scaffold as dopamine receptor 4 (D4R) antagonists. Bioorganic & Medicinal Chemistry Letters. 26: 5757-5764. PMID 28327307 DOI: 10.1016/J.Bmcl.2016.10.049  0.479
2016 Temple KJ, Wright EN, Fierke CA, Gibbs RA. Synthesis of Non-natural, Frame-Shifted Isoprenoid Diphosphate Analogues. Organic Letters. 18: 6038-6041. PMID 27934359 DOI: 10.1021/Acs.Orglett.6B02977  0.418
2016 Borza CM, Su Y, Tran TL, Yu L, Steyns N, Temple KJ, Skwark MJ, Meiler J, Lindsley CW, Hicks BR, Leitinger B, Zent R, Pozzi A. Discoidin domain receptor 1 kinase activity is required for regulating collagen IV synthesis. Matrix Biology : Journal of the International Society For Matrix Biology. PMID 27915093 DOI: 10.1016/J.Matbio.2016.11.009  0.405
2016 Duvernay MT, Temple KJ, Maeng JG, Blobaum AL, Stauffer SR, Lindsley CW, Hamm HE. Contributions of PAR1 and PAR4 to thrombin induced GPIIbIIIa activation in human platelets. Molecular Pharmacology. PMID 27784794 DOI: 10.1124/Mol.116.106666  0.481
2016 Temple KJ, Duvernay MT, Maeng JG, Blobaum AL, Stauffer SR, Hamm HE, Lindsley CW. Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles. Bioorganic & Medicinal Chemistry Letters. PMID 27777004 DOI: 10.1016/J.Bmcl.2016.10.020  0.458
2016 Temple KJ, Duvernay MT, Young SE, Wen W, Wu W, Maeng J, Blobaum AL, Stauffer SR, Hamm HE, Lindsley CW. Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with In Vivo Utility and Activity Against γ-Thrombin. Journal of Medicinal Chemistry. PMID 27482618 DOI: 10.1021/Acs.Jmedchem.6B00928  0.448
2016 Temple KJ, Wright EN, Fierke CA, Gibbs RA. Exploration of GGTase-I substrate requirements. Part 2: Synthesis and biochemical analysis of novel saturated geranylgeranyl diphosphate analogs. Bioorganic & Medicinal Chemistry Letters. PMID 27342751 DOI: 10.1016/J.Bmcl.2016.06.035  0.474
2016 Temple KJ, Wright EN, Fierke CA, Gibbs RA. Exploration of GGTase-I substrate requirements. Part 1: Synthesis and biochemical evaluation of novel aryl-modified geranylgeranyl diphosphate analogs. Bioorganic & Medicinal Chemistry Letters. PMID 27342750 DOI: 10.1016/J.Bmcl.2016.06.034  0.47
2016 Witt JO, McCollum AL, Hurtado MA, Huseman ED, Jeffries DE, Temple KJ, Plumley HC, Blobaum AL, Lindsley CW, Hopkins CR. Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D4R) antagonists. Bioorganic & Medicinal Chemistry Letters. PMID 27080176 DOI: 10.1016/J.Bmcl.2016.03.102  0.485
Show low-probability matches.